This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96. 10.1056/NEJMoa043330StuppRMasonWPvan den BentMJWellerMFisherBTaphoornMJet al.Radiotherapy plus concomitant and adjuvant temozolomide for glioblastomaN Engl J Med20053529879610.1056/NEJMoa043330Open DOISearch in Google Scholar
Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001; 95: 190-8. 10.3171/jns.2001.95.2.0190LacroixMAbi-SaidDFourneyDRGokaslanZLShiWDeMonteFet al.A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survivalJ Neurosurg200195190810.3171/jns.2001.95.2.0190Open DOISearch in Google Scholar
Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 2011; 115: 3-8. 10.3171/2011.2.JNS10998SanaiNPolleyMYMcDermottMWParsaATBergerMS.An extent of resection threshold for newly diagnosed glioblastomasJ Neurosurg20111153810.3171/2011.2.JNS10998Open DOISearch in Google Scholar
Stummer W, van den Bent MJ, Westphal M. Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion. Acta Neurochir (Wien) 2011; 153: 1211-8. 10.1007/s00701-011-1001-xStummerWvan den BentMJWestphalM.Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussionActa Neurochir (Wien)20111531211810.1007/s00701-011-1001-xOpen DOISearch in Google Scholar
Almenawer SA, Badhiwala JH, Alhazzani W, Greenspoon J, Farrokhyar F, Yarascavitch B, et al. Biopsy versus partial versus gross total resection in older patients with high-grade glioma: a systematic review and meta-analysis. Neuro Oncol 2015; 17: 868-81 10.1093/neuonc/nou349AlmenawerSABadhiwalaJHAlhazzaniWGreenspoonJFarrokhyarFYarascavitchBet al.Biopsy versus partial versus gross total resection in older patients with high-grade glioma: a systematic review and meta-analysisNeuro Oncol2015178688110.1093/neuonc/nou349Open DOISearch in Google Scholar
Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 2010; 120: 707-18. 10.1007/s00401-010-0781-zHartmannCHentschelBWickWCapperDFelsbergJSimonMet al.Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomasActa Neuropathol20101207071810.1007/s00401-010-0781-zOpen DOISearch in Google Scholar
Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360: 765-73. 10.1056/NEJMoa0808710YanHParsonsDWJinGMcLendonRRasheedBAYuanWet al.IDH1 and IDH2 mutations in gliomasN Engl J Med20093607657310.1056/NEJMoa0808710Open DOISearch in Google Scholar
Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343: 1350-4. 10.1056/NEJM200011093431901EstellerMGarcia-FoncillasJAndionEGoodmanSNHidalgoOFVanaclochaVet al.Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agentsN Engl J Med20003431350410.1056/NEJM200011093431901Open DOISearch in Google Scholar
Regula J, MacRobert AJ, Gorchein A, Buonaccorsi GA, Thorpe SM, Spencer GM, et al. Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5 aminolaevulinic acid induced protoporphyrin IX - a pilot study. Gut 1995; 36: 67-75.RegulaJMacRobertAJGorcheinABuonaccorsiGAThorpeSMSpencerGMet al.Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5 aminolaevulinic acid induced protoporphyrin IX - a pilot studyGut199536677510.1136/gut.36.1.67Search in Google Scholar
Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006; 7: 392-401. 10.1016/S1470-2045(06)70665-9StummerWPichlmeierUMeinelTWiestlerODZanellaFReulenHJet al.Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trialLancet Oncol2006739240110.1016/S1470-2045(06)70665-9Open DOISearch in Google Scholar
Valdes PA, Jacobs V, Harris BT, Wilson BC, Leblond F, Paulsen KD, et al. Quantitative fluorescence using 5-aminolevulinic acid-induced protoporphyrin IX biomarker as a surgical adjunct in low-grade glioma surgery. J Neurosurg 2015; 123: 771-80. 10.3171/2014.12.JNS14391ValdesPAJacobsVHarrisBTWilsonBCLeblondFPaulsenKDet al.Quantitative fluorescence using 5-aminolevulinic acid-induced protoporphyrin IX biomarker as a surgical adjunct in low-grade glioma surgeryJ Neurosurg20151237718010.3171/2014.12.JNS14391464661926140489Open DOISearch in Google Scholar
Ishihara R, Katayama Y, Watanabe T, Yoshino A, Fukushima T, Sakatani K. Quantitative spectroscopic analysis of 5-aminolevulinic acid-induced protoporphyrin IX fluorescence intensity in diffusely infiltrating astrocytomas. Neurol Med Chir (Tokyo) 2007; 47: 53-7; discussion 57.IshiharaRKatayamaYWatanabeTYoshinoAFukushimaTSakataniK.Quantitative spectroscopic analysis of 5-aminolevulinic acid-induced protoporphyrin IX fluorescence intensity in diffusely infiltrating astrocytomasNeurol Med Chir (Tokyo)200747537discussion 5710.2176/nmc.47.5317317941Search in Google Scholar
Roberts DW, Valdes PA, Harris BT, Fontaine KM, Hartov A, Fan X, et al. Coregistered fluorescence-enhanced tumor resection of malignant glioma: relationships between delta-aminolevulinic acid-induced protoporphyrin IX fluorescence, magnetic resonance imaging enhancement, and neuropathological parameters. Clinical article. J Neurosurg 2011; 114: 595-603. 10.3171/2010.2.JNS091322RobertsDWValdesPAHarrisBTFontaineKMHartovAFanXet al.Coregistered fluorescence-enhanced tumor resection of malignant glioma: relationships between delta-aminolevulinic acid-induced protoporphyrin IX fluorescence, magnetic resonance imaging enhancement, and neuropathological parameters. Clinical articleJ Neurosurg201111459560310.3171/2010.2.JNS091322292100820380535Open DOISearch in Google Scholar
Valdes PA, Kim A, Brantsch M, Niu C, Moses ZB, Tosteson TD, et al. ƌ-aminolevulinic acid-induced protoporphyrin IX concentration correlates with histopathologic markers of malignancy in human gliomas: the need for quantitative fluorescence-guided resection to identify regions of increasing malignancy. Neuro Oncol 2011; 13: 846-56. 10.1093/neuonc/nor086ValdesPAKimABrantschMNiuCMosesZBTostesonTDet al.ƌ-aminolevulinic acid-induced protoporphyrin IX concentration correlates with histopathologic markers of malignancy in human gliomas: the need for quantitative fluorescence-guided resection to identify regions of increasing malignancyNeuro Oncol2011138465610.1093/neuonc/nor086314547521798847Open DOISearch in Google Scholar
Jaber M, Wolfer J, Ewelt C, Holling M, Hasselblatt M, Niederstadt T, et al. The Value of 5-Aminolevulinic acid in low-grade gliomas and high-grade gliomas lacking glioblastoma imaging features: an analysis based on fluorescence, magnetic resonance imaging, 18F-fluoroethyl tyrosine positron emission tomography, and tumor molecular factors. Neurosurgery 2016; 78: 401-11; discussion 411. 10.1227/NEU.0000000000001020JaberMWolferJEweltCHollingMHasselblattMNiederstadtTet al.The Value of 5-Aminolevulinic acid in low-grade gliomas and high-grade gliomas lacking glioblastoma imaging features: an analysis based on fluorescence, magnetic resonance imaging, 18F-fluoroethyl tyrosine positron emission tomography, and tumor molecular factorsNeurosurgery20167840111discussion 41110.1227/NEU.0000000000001020474798026366972Open DOISearch in Google Scholar
Johansson A, Palte G, Schnell O, Tonn JC, Herms J, Stepp H. 5-Aminolevulinic acid-induced protoporphyrin IX levels in tissue of human malignant brain tumors. Photochem Photobiol 2010; 86: 1373-8. 10.1111/j.1751-1097.2010.00799.xJohanssonAPalteGSchnellOTonnJCHermsJSteppH.5-Aminolevulinic acid-induced protoporphyrin IX levels in tissue of human malignant brain tumorsPhotochem Photobiol2010861373810.1111/j.1751-1097.2010.00799.x20854414Open DOISearch in Google Scholar
Arita H, Kinoshita M, Kagawa N, Fujimoto Y, Kishima H, Hashimoto N, et al. (1)(1)C-methionine uptake and intraoperative 5-aminolevulinic acid-induced fluorescence as separate index markers of cell density in glioma: a stereotactic image-histological analysis. Cancer 2012; 118: 1619-27. 10.1002/cncr.26445AritaHKinoshitaMKagawaNFujimotoYKishimaHHashimotoNet al.(1)(1)C-methionine uptake and intraoperative 5-aminolevulinic acid-induced fluorescence as separate index markers of cell density in glioma: a stereotactic image-histological analysisCancer201211816192710.1002/cncr.2644521837671Open DOISearch in Google Scholar
Lau D, Hervey-Jumper SL, Chang S, Molinaro AM, McDermott MW, Phillips JJ, et al. A prospective Phase II clinical trial of 5-aminolevulinic acid to assess the correlation of intraoperative fluorescence intensity and degree of histologic cellularity during resection of high-grade gliomas. J Neurosurg 2016; 124: 1300-9. 10.3171/2015.5.JNS1577LauDHervey-JumperSLChangSMolinaroAMMcDermottMWPhillipsJJet al.A prospective Phase II clinical trial of 5-aminolevulinic acid to assess the correlation of intraoperative fluorescence intensity and degree of histologic cellularity during resection of high-grade gliomasJ Neurosurg20161241300910.3171/2015.5.JNS157726544781Open DOISearch in Google Scholar
Widhalm G, Kiesel B, Woehrer A, Traub-Weidinger T, Preusser M, Marosi C, et al. 5-Aminolevulinic acid induced fluorescence is a powerful intraoperative marker for precise histopathological grading of gliomas with nonsignificant contrast-enhancement. PLoS One 2013; 8: e76988. 10.1371/journal.pone.0076988WidhalmGKieselBWoehrerATraub-WeidingerTPreusserMMarosiCet al.5-Aminolevulinic acid induced fluorescence is a powerful intraoperative marker for precise histopathological grading of gliomas with nonsignificant contrast-enhancementPLoS One20138e7698810.1371/journal.pone.0076988380000424204718Open DOISearch in Google Scholar
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97-109. 10.1007/s00401-007-0243-4LouisDNOhgakiHWiestlerODCaveneeWKBurgerPCJouvetAet al.The 2007 WHO classification of tumours of the central nervous systemActa Neuropathol20071149710910.1007/s00401-007-0243-4192916517618441Open DOISearch in Google Scholar
Jenkinson MD, du Plessis DG, Smith TS, Joyce KA, Warnke PC, Walker C. Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain 2006; 129: 1884-91. 10.1093/brain/awl108JenkinsonMDdu PlessisDGSmithTSJoyceKAWarnkePCWalkerC.Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI featuresBrain200612918849110.1093/brain/awl10816670176Open DOISearch in Google Scholar
Colditz MJ, Jeffree RL. Aminolevulinic acid (ALA)-protoporphyrin IX fluorescence guided tumour resection. Part 1: Clinical, radiological and pathological studies. J Clin Neurosci 2012; 19: 1471-4. 10.1016/j.jocn.2012.03.009ColditzMJJeffreeRL.Aminolevulinic acid (ALA)-protoporphyrin IX fluorescence guided tumour resection. Part 1: Clinical, radiological and pathological studiesJ Clin Neurosci2012191471-410.1016/j.jocn.2012.03.00922959448Open DOISearch in Google Scholar
Agarwal S, Sharma MC, Jha P, Pathak P, Suri V, Sarkar C, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing. Neuro Oncol 2013; 15: 718-26. 10.1093/neuonc/not015AgarwalSSharmaMCJhaPPathakPSuriVSarkarCet al.Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencingNeuro Oncol2013157182610.1093/neuonc/not015366109823486690Open DOISearch in Google Scholar
Kim JE, Cho HR, Xu WJ, Kim JY, Kim SK, Kim SK, et al. Mechanism for enhanced 5-aminolevulinic acid fluorescence in isocitrate dehydrogenase 1 mutant malignant gliomas. Oncotarget 2015; 6: 20266-77. 10.18632/oncotarget.4060KimJEChoHRXuWJKimJYKimSKKimSKet al.Mechanism for enhanced 5-aminolevulinic acid fluorescence in isocitrate dehydrogenase 1 mutant malignant gliomasOncotarget20156202667710.18632/oncotarget.4060465300326008980Open DOISearch in Google Scholar
Lass U, Hartmann C, Capper D, Herold-Mende C, von Deimling A, Meiboom M, et al. Chromogenic in situ hybridization is a reliable alternative to fluorescence in situ hybridization for diagnostic testing of 1p and 19q loss in paraffin-embedded gliomas. Brain Pathol 2013; 23: 311-8. 10.1111/bpa.12003LassUHartmannCCapperDHerold-MendeCvon DeimlingAMeiboomMet al.Chromogenic in situ hybridization is a reliable alternative to fluorescence in situ hybridization for diagnostic testing of 1p and 19q loss in paraffin-embedded gliomasBrain Pathol201323311810.1111/bpa.12003802948523107103Open DOISearch in Google Scholar
Araki Y, Mizoguchi M, Yoshimoto K, Shono T, Amano T, Nakamizo A, et al. Quantitative digital assessment of MGMT immunohistochemical expression in glioblastoma tissue. Brain Tumor Pathol 2011; 28: 25-31.10.1007/s10014-010-0004-2ArakiYMizoguchiMYoshimotoKShonoTAmanoTNakamizoAet al.Quantitative digital assessment of MGMT immunohistochemical expression in glioblastoma tissueBrain Tumor Pathol201128253110.1007/s10014-010-0004-221249460Open DOISearch in Google Scholar
Widhalm G, Wolfsberger S, Minchev G, Woehrer A, Krssak M, Czech T, et al. 5-Aminolevulinic acid is a promising marker for detection of anaplastic foci in diffusely infiltrating gliomas with nonsignificant contrast enhancement. Cancer 2010; 116: 1545-52. 10.1002/cncr.24903WidhalmGWolfsbergerSMinchevGWoehrerAKrssakMCzechTet al.5-Aminolevulinic acid is a promising marker for detection of anaplastic foci in diffusely infiltrating gliomas with nonsignificant contrast enhancementCancer201011615455210.1002/cncr.2490320108311Open DOISearch in Google Scholar
Yang X, Palasuberniam P, Kraus D, Chen B. Aminolevulinic acid-based tumor detection and therapy: molecular mechanisms and strategies for enhancement. Int J Mol Sci 2015; 16: 25865-80. 10.3390/ijms161025865YangXPalasuberniamPKrausDChenB.Aminolevulinic acid-based tumor detection and therapy: molecular mechanisms and strategies for enhancementInt J Mol Sci201516258658010.3390/ijms161025865463283026516850Open DOISearch in Google Scholar
Frezza C, Zheng L, Folger O, Rajagopalan KN, MacKenzie ED, Jerby L, et al. Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature 2011; 477: 225-8. 10.1038/nature10363FrezzaCZhengLFolgerORajagopalanKNMacKenzieEDJerbyLet al.Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydrataseNature2011477225810.1038/nature1036321849978Open DOISearch in Google Scholar
Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 462: 739-44. 10.1038/nature08617DangLWhiteDWGrossSBennettBDBittingerMADriggersEMet al.Cancer-associated IDH1 mutations produce 2-hydroxyglutarateNature20094627394410.1038/nature08617281876019935646Open DOISearch in Google Scholar
Yu MO, Song NH, Park KJ, Park DH, Kim SH, Chae YS, et al. Romo1 is associated with ROS production and cellular growth in human gliomas. J Neurooncol 2015; 121: 73-81. 10.1007/s11060-014-1608-xYuMOSongNHParkKJParkDHKimSHChaeYSet al.Romo1 is associated with ROS production and cellular growth in human gliomasJ Neurooncol2015121738110.1007/s11060-014-1608-x25193023Open DOISearch in Google Scholar
Sasaki M, Knobbe CB, Itsumi M, Elia AJ, Harris IS, Chio, II, et al. D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. Genes Dev 2012; 26: 2038-49. 10.1101/gad.198200.112SasakiMKnobbeCBItsumiMEliaAJHarrisISChioIIet alD-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane functionGenes Dev20122620384910.1101/gad.198200.1121344473022925884Open DOISearch in Google Scholar
Liu Y, Liang Y, Zheng T, Yang G, Zhang X, Sun Z, et al. Inhibition of heme oxygenase-1 enhances anti-cancer effects of arsenic trioxide on glioma cells. J Neurooncol 2011; 104: 449-58. 10.1007/s11060-010-0513-1LiuYLiangYZhengTYangGZhangXSunZet al.Inhibition of heme oxygenase-1 enhances anti-cancer effects of arsenic trioxide on glioma cellsJ Neurooncol20111044495810.1007/s11060-010-0513-121327864Open DOISearch in Google Scholar
Belcher JD, Beckman JD, Balla G, Balla J, Vercellotti G. Heme degradation and vascular injury. Antioxid Redox Signal 2010; 12: 233-48. 10.1089/ars.2009.2822BelcherJDBeckmanJDBallaGBallaJVercellottiG.Heme degradation and vascular injuryAntioxid Redox Signal2010122334810.1089/ars.2009.2822282114619697995Open DOISearch in Google Scholar
Na HK, Surh YJ. Oncogenic potential of Nrf2 and its principal target protein heme oxygenase-1. Free Radic Biol Med 2014; 67: 353-65. 10.1016/j. freeradbiomed.2013.10.819NaHKSurhYJ.Oncogenic potential of Nrf2 and its principal target protein heme oxygenase-1Free Radic Biol Med2014673536510.1016/j. freeradbiomed.2013.10.819Open DOISearch in Google Scholar
Hagiya Y, Adachi T, Ogura S, An R, Tamura A, Nakagawa H, et al. Nrf2-dependent induction of human ABC transporter ABCG2 and heme oxygenase-1 in HepG2 cells by photoactivation of porphyrins: biochemical implications for cancer cell response to photodynamic therapy. J Exp Ther Oncol 2008; 7: 153-67.HagiyaYAdachiTOguraSAnRTamuraANakagawaHet al.Nrf2-dependent induction of human ABC transporter ABCG2 and heme oxygenase-1 in HepG2 cells by photoactivation of porphyrins: biochemical implications for cancer cell response to photodynamic therapyJ Exp Ther Oncol2008715367Search in Google Scholar
Mukasa A, Takayanagi S, Saito K, Shibahara J, Tabei Y, Furuya K, et al. Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients. Cancer Sci 2012; 103: 587-92. 10.1111/j.1349-7006.2011.02175.xMukasaATakayanagiSSaitoKShibaharaJTabeiYFuruyaKet al.Significance of IDH mutations varies with tumor histology grade, and genetics in Japanese glioma patientsCancer Sci20121035879210.1111/j.1349-7006.2011.02175.x771360922136423Open DOISearch in Google Scholar
Wang HY, Tang K, Liang TY, Zhang WZ, Li JY, Wang W, et al. The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas. J Exp Clin Cancer Res 2016; 35: 86. 10.1186/s13046-016-0362-7WangHYTangKLiangTYZhangWZLiJYWangWet al.The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomasJ Exp Clin Cancer Res2016358610.1186/s13046-016-0362-7488866827245697Open DOISearch in Google Scholar
Ballester LY, Olar A, Roy-Chowdhuri S. Next-generation sequencing of central nervous systems tumors: the future of personalized patient management. Neuro Oncol 2016; 18: 308-10. 10.1093/neuonc/nov329BallesterLYOlarARoy-ChowdhuriS.Next-generation sequencing of central nervous systems tumors: the future of personalized patient managementNeuro Oncol2016183081010.1093/neuonc/nov329476724826917589Open DOISearch in Google Scholar
